Physician profile
Jerod C Walker
NPI 1952684227
$6,118.32
in general payments reported to CMS, 2019-2025
32 companies · $924 in 2025
The $924 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,628 · 2020: $304 · 2021: $828 · 2022: $543 · 2023: $779 · 2024: $1,111 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,812 · Education: $2.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,811.83 |
| Education | $2.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,009.68 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $958.82 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $442.24 | 2021-2025 | Vraylar |
| Pfizer INC. | $370.30 | 2019-2025 | |
| Amgen INC. | $299.41 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $298.28 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.16 | 2019-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $278.24 | 2019-2025 | Trintellix, Glassia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.60 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $231.70 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $211.65 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $149.04 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $146.10 | 2024-2025 | Rexulti |
| Allergan, INC. | $139.46 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $128.68 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $120.51 | 2019-2025 | Trelegy Ellipta |
| Lundbeck LLC | $114.00 | 2020-2025 | Rexulti |
| Amarin Pharma, INC. | $106.94 | 2019-2021 | |
| Exact Sciences Corporation | $100.34 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $91.74 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $62.48 | 2021 | |
| Dexcom, INC. | $58.18 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $48.74 | 2019-2022 | |
| Grifols USA, LLC | $42.68 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.06 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.72 | 2025 | Caplyta |
| Inspire Medical Systems, INC. | $22.30 | 2024 | Inspire |
| Xeris Pharmaceuticals, INC. | $21.62 | 2024 | Gvoke Hypopen |
| Ironwood Pharmaceuticals, INC | $15.35 | 2020 | |
| Aimmune Therapeutics, INC. | $13.71 | 2025 | Zenpep |
| Sanofi-Aventis U.S. LLC | $12.15 | 2019 | |
| Travere Therapeutics, INC. | $2.44 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerod Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.